Suzhou Yilian Biopharmaceutical

MediLink Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes its proprietary MediLinker™ platform to design ADCs with improved therapeutic windows by enhancing stability in circulation and ensuring efficient payload release within the tumor microenvironment. Its pipeline includes several high-potential candidates, such as YL201 and YL202, which are currently undergoing clinical evaluation for various solid tumors. MediLink has established significant global partnerships with industry leaders including BioNTech, Roche, and Johnson & Johnson to co-develop and commercialize its innovative assets. The company is led by a management team with extensive experience in ADC research and global drug development.